EC Gastroenterology and Digestive System

Literature Review Volume 10 Issue 6 - 2023

Perianal Disease in Idiopathic Inflammatory Bowel Disease. Updated Approaches to its Management

Ioannis Triantafyllakis1, Maria Saridi2*, Aikaterini Toska2, Eleni N Albani3, Constantinos Togas4, Dimitrios K Christodoulou1 and Konstantinos H Katsanos1

1Department of Gastroenterology, University Hospital of Ioannina, Ioannina, Greece

2Department of Nursing, University of Thessaly, Larissa, Greece

3Department of Nursing, University of Patra, Patra, Greece

4Social Worker-Psychologist, Post-Doc Researcher, Panteion University of Social and Political Sciences, Athens, Greece

*Corresponding Author: Maria Saridi, Assistant Professor, Department of Nursing, University of Thessaly, Larissa, Greece.
Received: June 19, 2023; Published: June 27, 2023

Perianal crohn disease is defined as an inflammation at or near the anus, including tags, stenosis, fistulae and abscesses. Perianal disease is a major source of morbidity and a common complication in these patients and in patients with Inflammatory bowel disease in general. Perianal fistulas and abscesses are common manifestations of crohn's disease. Perianal crohn’s affects similar numbers of men and women, but women are at greater risk for further complications in the vaginal wall. Diagnosis requires a detailed history, physical and clinical examination, and assessment of luminal disease. It can lead to difficult treatment procedures, a high rate of surgeries, and a low quality of life. The optimum management of perianal disease requires the interdisciplinary collaboration of medical specialties with imaging and systematic clinical and endoscopic evaluation, combined with medical and surgical management and continuous monitoring of these patients.

Keywords: Perianal Crohn Disease; Fistula; Abscesses; Crohn's Disease; Inflammatory Bowel Disease

  1. Molodecky NA., et al. “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review”. Gastroenterology 142 (2012): 46-54.e42.
  2. Loftus EV. “Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences”. Gastroenterology 126 (2004): 1504-1517.
  3. Fabián O and Kamaradová K. “Morphology of inflammatory bowel diseases (IBD)”. Ceskoslovenská Patologie 1 (2022): 27-37.
  4. Ford AC., et al. “Ulcerative colitis”. British Medical Journal 5346 (2013): f432.
  5. Ordas, I., et al. “Ulcerative colitis”. Lancet 380 (2012): 1606-1619.
  6. Sutherland L and MacDonald J. “Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis”. In: The Cochrane Database of Systematic Reviews (edition Sutherland L). Chichester: John Wiley and Sons, Ltd (2003): CD000543.
  7. Zwintscher NP., et al. “The impact of perianal disease in young patients with inflammatory bowel disease”. The International Journal of Colorectal Disease 9 (2015): 1275-1279.
  8. Gajendran M., et al. “A comprehensive review and update on Crohn's disease”. Disease-a-Month Journal 2 (2018): 20-57.
  9. Gearry RB. “IBD and Environment: Are There Differences between East and West”. Digital Distribution 1-2 (2016): 84-89.
  10. Kaplan GG. “The global burden of IBD: from 2015 to 2025”. Nature Reviews Gastroenterology and Hepatology 12 (2015): 720-727.
  11. Lestár B and Nagy F. “Surgical management of inflammatory bowel diseases”. Orvosi Hetilap 2 (2004): 51-58.
  12. Kühn F., et al. “Risikofaktoren für einenfrühen OP-Zeitpunkt und chirurgische Komplikationenbei Morbus Crohn” [Risk Factors for Early Surgery and Surgical Complications in Crohn's Disease]”. Zentralblatt fur Chirurgie 6 (2018): 596-602.
  13. Siegel CA. “Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options”. Gut 61 (2012): 459-465.
  14. Van Gennep S., et al. “Impaired Quality of Working Life in Inflammatory Bowel Disease Patients”. Digestive Diseases and Sciences 9 (2021): 2916-2924.
  15. Cosnes J., et al. “Epidemiology and natural history of inflammatory bowel dis-eases”. Gastroenterology 140 (2011): 1785-1794.e4.
  16. Bohl JL and Sobba K. “Indications and options for surgery in ulcerative colitis”. Surgical Clinics of North America 95 (2015): 1211-1232.
  17. Baker DM., et al. “A systematic review and meta-analysis of outcomes after elective surgery for ulcerative colitis”. Colorectal Disease 1 (2021): 18-33.
  18. Moon CM., et al. “Clinical features and predictors of clinical outcomes in Korean patients with Crohn's disease: a Korean association for the study of intestinal diseases multicenter study”. Journal of Gastroenterology and Hepatology 1 (2014): 74-82.
  19. Zhao M., et al. “A 10-year follow-up study of the natural history of perianal Crohn's disease in a Danish population-based inception cohort”. Inflammatory Bowel Diseases 7 (2019): 1227-1236.
  20. Baumgart DC and Sandborn WJ. “Crohn's disease”. The Lancet 9853 (2012): 1590-1605.
  21. Höög CM., et al. “Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn’s disease”. Scandinavian Journal of Gastroenterology 9 (2014): 1084-1090.
  22. D' Ugo S., et al. “Hemorrhoids and anal fissures in inflammatory bowel disease”. Minerva Gastroenterologica e Dietologica 4 (2015): 223-233.
  23. Kelley KA., et al. “Perianal Crohn's disease: challenges and solutions”. Clinical and Experimental Gastroenterology 10 (2017): 39-46.
  24. Schwartz DA., et al. “The natural history of fistulizing Crohn's disease in Olmsted County”. Minnesota Gastroenterology 4 (2002): 875-880.
  25. Sandborn WJ., et al. “American Gastroenterological Association Clinical Practice C AGA technical review on perianal Crohn’s disease”. Gastroenterology5 (2003): 1508-1530.
  26. Tarrant KM., et al. “Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype”. The American Journal of Gastroenterology 12 (2008): 3082-3093.
  27. Faucheron JL., et al. “Long-term seton drainage for high anal fistulas in Crohn’s disease - a sphincter-saving operation?” Diseases of the Colon and Rectum 2 (1996): 208-211.
  28. Tozer PJ., et al. “Etiology of perianal Crohn’s disease: role of genetic, microbiological, and immunological factors”. Inflammatory Bowel Diseases 10 (2009): 1591-1598.
  29. Mutanen A and Pakarinen MP. “Perianal Crohn's Disease in Children and Adolescents”. European Journal of Pediatric Surgery 5 (2020): 395-400.
  30. Platell C., et al. “Anal pathology in patients with Crohn’s disease”. ANZ Journal of Surgery 66 (1996): 5-9.
  31. Stein BL and Gordon PH. “Perianal inflammatory conditions in inflammatory bowel disease”. Current Opinion in General Surgery (1993): 141-146.
  32. Panés J and Rimola J. “Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy”. Nature Reviews Gastroenterology and Hepatology 11 (2017): 652-664.
  33. Solomon MJ. “Fistulae and abscesses in symptomatic perianal Crohn's disease”. The International Journal of Colorectal Disease 5 (1996): 222-226.
  34. Makowiec F., et al. “Perianal abscess in Crohn's disease”. Diseases of the Colon and Rectum 4 (1997): 443-450.
  35. Thomas T., et al. “The risk of inflammatory bowel disease in subjects presenting with Perianal Abscess: findings from the THIN Database”. Journal of Crohn's and Colitis 5 (2019): 600-606.
  36. Van Outryve M., et al. “Value of transrectal ultrasonography in Crohn’s disease”. Gastroenterology 101 (1991): 1171-1177.
  37. Beaugerie L., et al “Predictors of Crohn's disease”. Gastroenterology 130 (2006): 650-656.
  38. Han YM., et al. “Patients with perianal Crohn's disease have poor disease outcomes after primary bowel resection”. Journal of Gastroenterology and Hepatology 8 (2016): 1436-1442.
  39. Zwintscher NP., et al. “The impact of perianal disease in young patients with inflammatory bowel disease”. The International Journal of Colorectal Disease 9 (2015): 1275-1279.
  40. Regueiro M. “The role of endoscopy in the evaluation of fistulizing Crohn’s disease”. Gastrointestinal Endoscopy Clinics of North America Journal 3 (2002): 621-633.
  41. Black C and Ford A. “Global burden of irritable bowel syndrome: Trends, predictions and risk factors”. Nature Reviews Gastroenterology and Hepatology 8 (2020): 473-486.
  42. Pescatori M., et al. “Management of perianal Crohn’s disease. Results of a multicentre study in Italy”. Diseases of the Colon and Rectum 38 (1995): 121-124.
  43. Lee MJ., et al. “Surgical management of fistulating perianal Crohn's disease: a UK survey”. Colorectal Disease3 (2017): 266-273.

Maria Saridi., et al. "Perianal Disease in Idiopathic Inflammatory Bowel Disease. Updated Approaches to its Management". EC Gastroenterology and Digestive System  10.6 (2023): 01-08.